Media stories about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.8219384873181 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
- Achillion Pharmaceuticals, Inc. (ACHN) stock price expected to reach at $5.36 in next 52-week (analystrecommendation.com)
- Achillion Pharmaceuticals (ACHN) Cut to “Hold” at BidaskClub (americanbankingnews.com)
- Signals from Technical Perspective – Achillion Pharmaceuticals Inc (NASDAQ: ACHN) (stockspen.com)
- Read This Before Trade: Helios and Matheson Analytics Inc. (HMNY), Achillion Pharmaceuticals, Inc. (ACHN) (nmsunews.com)
- Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.14 Per Share (americanbankingnews.com)
ACHN remained flat at $$3.49 on Friday. 1,057,497 shares of the company’s stock traded hands, compared to its average volume of 1,926,989. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66. The firm has a market capitalization of $481.25, a price-to-earnings ratio of -5.63 and a beta of 0.89.
Several brokerages have weighed in on ACHN. BidaskClub lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 27th. B. Riley began coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 target price on the stock. Finally, Leerink Swann restated a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.89.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.